Evox Therapeutics signs US$1.2bn deal with...Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases. more ➔
Calliditas Therapeutics raise US$90m in Na...Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO. more ➔
Hyloris Pharmaceuticals prepared to go pub...Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels. more ➔
NodThera bags US$55m in Series B roundNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement. more ➔
Bacterial colonisation differs by tumour t...An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities. more ➔
New algorithm predicts rheumatoid arthriti...Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases. more ➔
Novo Holdings invests into AI CRO ExScient...Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company. more ➔
Poxel SA raises €17.7m through capital i...Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors. more ➔
British scientists start Phase II on COVID...Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers. more ➔
SARS-CoV2 antibody tests: not suited for i...An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses. more ➔
